Garrido-Laguna et al. conducted a phase I study to evaluate decitabine in combination with panitumumab (an antibody against EGFR) in wild-type KRAS metastatic colorectal cancer (mCRC) patients. Here, EGFR is linked to metastatic colorectal cancer.